The HDAC1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the HDAC1 gene in human 143B osteosarcoma cells. This loss-of-function model enables investigation of HDAC1-dependent mechanisms without transient knockdown limitations. The polyclonal nature provides a heterogeneous edited population, reflecting a range of gene disruption outcomes. These cells serve as a robust tool for probing HDAC1’s roles in chromatin biology and oncogenic signaling.
The 143B cell line is derived from a human osteosarcoma and displays adherent, fibroblast-like morphology. Commonly used as an osteosarcoma model, it retains aggressive growth and metastatic characteristics. This host background provides a clinically relevant context for studying HDAC1 in bone cancer, a disease with frequently dysregulated epigenetic control. The active signaling and transcriptional programs in 143B cells allow physiologically meaningful exploration of HDAC1-mediated regulatory networks.
HDAC1 deacetylates histone H3 and H4 lysine residues, promoting chromatin compaction and transcriptional repression. It also targets non-histone proteins including p53, E2F1, STAT3, NF-??B, and MyoD, affecting cell cycle, apoptosis, and differentiation. HDAC1 resides in complexes with SIN3A, NuRD, and CoREST, interacting with SIN3A, MTA2, and RbAp46/48. Its activity is controlled by upstream kinases (CK2, PKA) and growth factors (EGF, TGF-??). Knockout of HDAC1 leads to histone hyperacetylation, derepression of gene expression, and induction of cell cycle arrest and apoptosis.
In osteosarcoma, HDAC1 is often linked to transcriptional silencing that fuels tumor progression. The 143B knockout model enables dissection of HDAC1 loss on acetylation marks (e.g., H3K9ac, H4ac), gene expression changes, and cellular phenotypes. Researchers can assess sensitivity to HDAC inhibitors, connecting basic chromatin biology with therapeutic investigation. This model is valuable for uncovering HDAC1-dependent vulnerabilities in bone cancer.
Applications include Western blotting and ChIP-qPCR for histone modifications, RT-qPCR and RNA-seq for gene expression analysis, and functional assays such as cell viability, apoptosis, and cell cycle flow cytometry. These cells facilitate drug target validation for HDAC inhibitors and studies of transcriptional regulation. For further assistance, contact Ascent Research.
